title: Preservation of the liver graft with Celsior solution.
abstract: BACKGROUND
  We studied the evolution of the liver graft with preservation in Celsior (CS) compared with University of Wisconsin solution (UW).
  
  
  METHODS
  A randomized prospective clinical study in 80 liver transplants (OLTs) from May 2001 to October 2003, compared CS (group I; n = 40) and UW (group II; n = 40). The characteristics of the donors were homogeneous, with no significant differences in 15 variables. CS was perfused with 4 L through the aorta, 2 L through the portal vein, and 1 L, through the portal vein on the back table; and the UW, as 3 L, 2 L, and 1 L, respectively. All OLTs were performed using the piggyback technique.
  
  
  RESULTS
  Group I experienced reperfusion syndrome (n = 2; 5.9%), primary graft nonfunction (n = 0); vascular complications (n = 0); biliary anastomosis stenosis (n = 8; 22.9%), intensive care unit (ICU) days (n = 4.1 +/- 1), death within 30 days (n = 1; 3.1%). The patient and graft survivals at 1, 3, 6, 12, and 24 months were 93.7%, 93.7%, 90.2%, 85.7%, 85.7%, and 94.3%, 88.5%, 85.2%, 78%, 78%, respectively. For group II; the reperfusion syndrome occured in 6 patients (17.6%); primary graft nonfunction (n = 0); vascular complications (n = 0), biliary anastomosis stenosis (n = 3; 8.6%), ICU days (n = 4.9 +/- 2.4) and death within 30 days (n = 1; 3.1%); The patient and graft survival at 1, 3, 6, 12, and 24 months were 96.9%, 93.5%, 89.8%, 79.8%, 79.8% and 94.3%, 88.3%, 84.9%, 75.5%, 66.1%, respectively.
  
  
  CONCLUSIONS
  CS offers the similar safety to UW for preservation of liver grafts within these ischemia times.
authors.affiliation: Liver Transplant Unit, Hospital Clínico Universitario. "Lozano Blesa," Zaragoza, Spain. agarciagil@telefonica.net
authors.forename: F A
authors.initials: FA
authors.lastname: García-Gil
authors.forename: J
authors.initials: J
authors.lastname: Arenas
authors.forename: A
authors.initials: A
authors.lastname: Güemes
authors.forename: E
authors.initials: E
authors.lastname: Esteban
authors.forename: E
authors.initials: E
authors.lastname: Tomé-Zelaya
authors.forename: F
authors.initials: F
authors.lastname: Lamata
authors.forename: R
authors.initials: R
authors.lastname: Sousa
authors.forename: A
authors.initials: A
authors.lastname: Jiménez
authors.forename: M E
authors.initials: ME
authors.lastname: Barrao
authors.forename: M T
authors.initials: MT
authors.lastname: Serrano
mesh_terms: D000241:Adenosine; D000328:Adult; D000368:Aged; D000493:Allopurinol; D004187:Disaccharides; D004573:Electrolytes; D005260:Female; D005971:Glutamates; D005978:Glutathione; D006639:Histidine; D006801:Humans; D007328:Insulin; D008099:Liver; D016031:Liver Transplantation / Q000502:physiology*; D008297:Male; D008353:Mannitol; D008875:Middle Aged; D009926:Organ Preservation / Q000379:methods*; D019188:Organ Preservation Solutions; D011169:Portal Vein / Q000601:surgery; D011183:Postoperative Complications / Q000145:classification / Q000453:epidemiology; D011446:Prospective Studies; D011887:Raffinose; D015424:Reperfusion; D015427:Reperfusion Injury / Q000453:epidemiology; D016896:Treatment Outcome; D014652:Vascular Diseases / Q000453:epidemiology
chemical_list: C088453:Celsior; D004187:Disaccharides; D004573:Electrolytes; D005971:Glutamates; D007328:Insulin; D019188:Organ Preservation Solutions; C055206:University of Wisconsin-lactobionate solution; D008353:Mannitol; D006639:Histidine; D000493:Allopurinol; D005978:Glutathione; D000241:Adenosine; D011887:Raffinose